Research, development, production and support of single and combinational approaches for clinical trials- broadly neutralizing monoclonal antibodies
Ended Awarded Last action
- Contract number
- HHSN26100045
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,219,506
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 57% obligated
-
- $2,219,506.29 Current, with exercised options
- $3,918,258.29 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $95,525 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Original award | $2,123,981 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 18, 2017, with a ceiling value of $3,918,258.29 for research, development, production, and support of single and combinational approaches for clinical trials using broadly neutralizing monoclonal antibodies.
Place of performance is Frederick, MD. The order carries an ultimate completion date of June 30, 2020. Pricing is cost plus fixed fee. No set-aside was used. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center contractor subsidiary of Leidos Holdings, Inc., providing biomedical research and facilities support services to the National Institutes of Health and National Cancer Institute.
Quick answers
Who was awarded contract HHSN26100045?
HHSN26100045 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2017.
How much is contract HHSN26100045 worth?
The government has obligated $2,219,506 on HHSN26100045. Its potential value, with all options, is $3,918,258.
Which agency awarded contract HHSN26100045?
National Cancer Institute (National Institutes of Health) awarded HHSN26100045, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract HHSN26100045 an order under another contract?
Yes. HHSN26100045 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100045 competed?
The extent of competition for HHSN26100045 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award